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Summary Cyclin E gene alteration in the cell cycle plays an important role in carcinogenesis, while p53 protein affects different phase
checkpoint pathways by activating p21 WAF1iCIPi in the normal cell cycle. We immunohistochemically examined the expression of cyclin E and
p53 proteins in 121 patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter to determine their significance for tumour
behaviour and patient prognosis. Cyclin E and p53 immunostaining of the nucleus was observed in 36 tumours (29.8%) and 35 tumours
(28.9%) respectively. A significant percentage, 69.4% (25 out of 36 tumours), of the cyclin E-positive tumours exhibited simultaneous labelling
for p53 (P < 0.05). Mirror-section technique was performed in five selected double-positive tumours to identify cancer cells that were nuclei
positive for both cyclin E and p53. The prevalence of cases simultaneously exhibiting both cyclin E and p53 immunostaining was higher in the
high-grade tumours (P< 0.01) than in the othertypes oftumours. Patients with TCCscoexpressing cyclin E and p53 had asignificantly poorer
prognosis than those expressing neither cyclin E nor p53 (P < 0.001). These in vivo findings provide evidence for cyclin E protein
overexpression in TCCs intimately associated with p53 alteration and suggest that simultaneous overexpression of both cyclin E and p53 is
related to tumour behaviour and poor prognosis.
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Cell cycle progression is governed by the sequential formation and
degradation of a series of multiple cyclins (Pines et al, 1989;
Hunter et al, 1991; Cordon-Cardo et al, 1995). Human cyclins,
such as A-type, B-type andGI (C, D and E)-type cyclins, complex
with and activate several cyclin-dependent kinases (Cdks) (Pines
et al, 1989), and they play an important role in the control ofmajor
checkpoints of the cell cycle (Hunter et al, 1991; Cordon-Cardo
et al, 1995). With the discovery of inappropriate expression of
cyclins in some tumours, it has now been specifically hypothe-
sized that some cyclins are intimately involved in oncogenesis;
acting as proto-oncogenes (Hunter et al, 1991; Cordon-Cardo et al,
1995). Diverse patterns of redundant expression of particular
cyclins, such as cyclins DI and E, in different tumour cell lines or
excised human carcinoma tissues have previously been reported in
oncogenesis (Buckley et al, 1993; Jiang et al, 1993; Keyomarsi
and Pardee, 1993; Leach et al, 1993; Cong et al, 1994; Gillett et al,
1994; Jares et al, 1994; Keyomarsi et al, 1994; Betticher et al,
1995; Keyomarsi et al, 1995; Michalides et al, 1995; Yasui et al,
1996; Ishikawa et al, 1997). In contrast to cyclin Dl, few data are
available regarding the cyclin E analysis of excised human carci-
noma tissues (Buckley et al, 1993; Keyomarsi et al, 1994, 1995;
Yasui et al, 1996). Furthermore, no study has demonstrated the
expression ofcyclin E in transitional cell carcinoma (TCC) of the
renal pelvis and ureter.
Oncogenic studies have recently revealed that mutations of the
p53 gene lead to overexpression ofthe p53 product in many kinds
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oftumours, and that these mutations are among the most common
genetic alterations in human cancers, including urothelial cancers
(Sidransky et al, 1991; Furihata et al, 1993, 1995a and b, 1996). In
addition, the usefulness of p53 as a prognostic indicator in TCCs
has generally been addressed, because tumours with p53 gene
mutations and/or protein accumulation often behave more aggres-
sively, although the mechanism by which p53 alteration affects the
clinical outcome is unknown (Furihata et al, 1993, 1995a). It has
been shown that the wild-type p53 normally controls cell cycle
checkpoints by activating p2lwAF1w/cw1, which is transcriptionally
regulated by p53, and inactivates cyclin D-Cdk4 as well as cyclin
E-Cdk2 complexes to regulate the normal cell cycle transitions
(El-Deiry et al, 1993; Harper et al, 1993). These findings suggest a
potential link between p53 and cyclin-Cdk complexes, including
cyclin E-Cdk2, in cell cycle regulation and tumour progression. A
recent immunohistochemical study with colorectal tumours has
demonstrated a significant correlation between the expression of
cyclin E and p53 protein (Yasui et al, 1996).
In the present study, we extended these observations ofcyclin E
and p53 to in vivo conditions by examining the relationship
between cyclin E and p53 alteration in human TCCs to elucidate
the potential role ofthese two factors in tumour development and
to assess their prognostic value. Their relationship with various
clinicopathological factors was then determined.
MATERIALS AND METHODS
Patients and tumour samples
One hundred and twenty-one cases of human TCCs of the renal
pelvis and ureter obtained by radical nephroureterectomy between
1981 and 1997 at the Department of Urology, Kochi Medical
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School, and the Divisions of Urology at both the Kochi Takasu
Hospital and the Fujisaki Hospital were studied using immuno-
histochemistry. Tumours were processed in a similar fashion at all
three institutions. Histological or clinical classification oftumours
was performed according to the 'General Rules for Clinical and
Pathological Studies on Renal Pelvic and Ureteral Cancer (1990)'.
Tumour specimens were fixed in 10% buffered formalin,
processed routinely and embedded in paraffin. In addition, of 121
tumours, 26 tumours already analysed for p53 gene mutations
(Furihata et al, 1995b) were prepared for the comprehensive study
ofcyclin E alteration. In each case, all the available haematoxylin
and eosin-stained sections were reviewed, and a representative
block with the maximum cut-surface of each tumour was chosen
for further studies. There were 68 renal pelvic cancers and 53
ureteral cancers (including ten cases with renal pelvic and ureteral
cancers). Of 121 cases with TCCs, 21 had bladder cancer concur-
rent with renal pelvic or ureteral cancer. The patients included 84
men and 37 women, ages 45-93 years (mean age 71.4 year).
Immunohistochemistry with cyclin E and p53
antibodies
For immunohistochemical study, 5-jg-thick sections from
archival formalin-fixed paraffin-embedded tissue were placed on
poly-L-lysine-coated slides (Sigma Chemical, St Louis, MO,
USA). Cyclin E or p53 protein expression were assessed by
immunohistochemical examination (streptavidin-biotin complex
procedure) with each monoclonal antibody, cyclin E (NCL-
Cyclin E, 13A3, IgG2a, dilution 1:50; Novocastra Laboratories,
Newcastle upon Tyne, UK) and p53 (p53, Ab-2; PAbI801, IgGI,
dilution 1:30; Calbiochem, MA USA). Preliminary studies also
showed that, as an alternative, autoclave treatment can be used to
expose the antigenic determinant in routine, formalin-fixed
material while retaining satisfactory morphological preservation
(Furihata et al, 1996). Therefore, deparaffinized tissue sections
were placed in 10 mm citrate buffer, pH 6.0, and heated to 132°C
in an autoclave for 20 min for antigen retrieval. After blockage of
endogenous peroxidase activity with methanol containing 0.3%
hydrogen peroxide for 30 min, the sections were incubated at 4°C
overnight with each monoclonal antibody to cyclin E and p53
protein respectively. After washing with 0.1 M phosphate-buffered
saline (PBS, pH 7.4), the streptavidin-biotin complex (ABC)
procedure was performed using a streptavidin-biotin complex
peroxidase kit (Dako LSAB kit, Dakopatts, Kyoto, Japan) and
Table 1 Summary of the association between the immunoreaction of cyclin
E and p53 in 121 cases of TCCs
Cyclin E-positive Cyclin E- Total
cases negative no. of cases
case
20-70% > 70%
p53-positive cases
20-70% 1 1 2 4
> 70% 6 17 8 31
p53-negative cases 2 9 75 86
Total no. of cases 9 27 85
following the directions in the kit manual. Finally, slides were
counterstained with methyl green. Positive or negative controls
included in each experiment were run in parallel; these included
replacement of the specific or non-specific mouse IgG1 or IgG2a
antibodies with PBS. The experiment was repeated, yielding
essentially identical patterns ofcyclin E orp53 distribution in each
instance in each tumour specimen.
In each case 300 tumourcells were counted with ax40 objective
afterfirst selecting the field that stained most densely at low power.
Tumour sections exhibiting definite staining of tumour cell nuclei
with cyclin E or p53 antibody were scored as cyclin E or p53 posi-
tive. A visual assessment was made in such cases ofthe number of
positive tumour cells as a proportion of the total expression of
cyclin E or p53 protein as follows: negative case (0%; or variable
weakpositivity in tumourcells, 0-20%); positive case consisting of
two patterns, one with heterogeneous (variable positivity in tumour
cells, 20-70%) and the other with homogenous (diffuse strong
positivity in tumour cells, > 70%) immunostaining. This criteria is
modified based on the methods by Terrell et al (1995).
Mirror section analysis of cyclin E and p53
immunopositivity
Two serial 3-jim-thick sections were obtained with the cut surfaces
facing each other. Each section was then individually reacted with
anti-cyclin E or -p53 antibody using immunohistochemistry, as
described above.
Statistical analysis
The correlations between the expression of cyclin E and/or p53
protein and the various clinicopathological factors considered
were determined using the chi-square test at the 5% level.
Association between cyclin E and/or p53
overexpression and prognosis
Survival was calculated from operation to the date of death or the
date of the last follow-up (either a clinical visit or a discussion
with the patient's referring physician). All patients were clinically
followed-up for more than 6 months, and there were no patients
with inadequate follow-up. Median follow-up was 3.4 years (range
0.5-10.5 years). Atlastfollow-up, 66.7% ofthe patients were alive.
Analysis of survival data was performed using survival curves
and the Kaplan-Meier method and log-rank test. In addition, the
Coxproportional hazards model, with P < 0.05 considered to be of
statistical significance, was used to calculate and estimate the post-
operative survival rate and to determine the significance of each
prognostic factor used in histological or clinical classification. For
multivariate analysis, variables were selected on condition that
they were statistically significant and were only poorly correlated
with each other (correlation coefflcient P < 0.4).
RESULTS
Immunohistochemistry with cyclin E and p53
antibodies
Table 1 summarizes the association between the cyclin E and the
p53 immunoreactivity in 121 cases of TCCs. The homogenous
nuclear immunoreactivity with cyclin E antibody was detected in
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Figure 1 Positive immunostaining of identical cancer cell nuclei with both
anti-cyclin E (A) and -p53 (B) antibodies (TCC of renal pelvis, grade 3;
x 300). G, glomerulus
22.3% (27 out of 121) of the TCCs. Staining was predominantly
observed in the nucleus. The heterogeneous nuclear staining in the
neoplastic cell population of immunoreactive cases was observed
in 7.4% (9 out of 121). In the normal tissues of the urinary tract,
cyclin E immunoreactivity was restricted to a subset ofcells ofthe
basal layer in the transitional epithelium and some invading
lymphocytes and histiocytes. These observations of reasonable
expression ofcyclin Eprovided additional supporting evidence for
the specificity ofthis antibody to detect cyclin E protein.
Positive staining with the anti-p53 antibody was detected in
28.9 % (35 out of 121) ofthe TCCs, including 25 tumours simultane-
ously labelled with cycin E antibody. p53 immunostaining was
homogeneous and intense in 31 tumours, and the positive reaction
was restricted to the nucleus. Theheterogeneous p53 immunostaining
was found in fourtumours. p53 immunostaining was negative in most
Table 2 Summary of the relationship between the cyclin E and/or p53 immunoreactivity and clinicopathological factors in 121 cases
of TCCs
Group I GroupII Group Ill Group IV Total
(cyclin E- (cyclin E- (cyclin E+ (cyclin E- no. of cases
/p53-) /p53+) /p53-) /p53+)
(75 cases) (Ten cases) (11 cases) 25 cases)
Age (years)
< 70 36 7 3 11 57
70-80 30 2 3 10 45
>80 9 1 5 4 19
Sex
Male 53 7 7 17 84
Female 22 3 4 8 37
Gradea
1,1 >2 11 1 2 1 15
2,2>3orl 44 3 5 6 58
3,3>2 20 6 4 18 48
(P< 0.01)
pTa
is, a 20 1 2 1 24
1 17 4 1 2 24
2 10 2 3 6 21
3 24 2 2 10 38
4 4 1 3 6 14
LY or Va
(-) 53 8 7 16 84
(+) 22 2 4 9 37
M or Na
(-) 71 9 6 17 103
(+) 4 1 5 8 18
Growtha
Invasive 55 9 7 22 93
NIT 12 6 3 10
PIT 43 3 4 12
Non-invasive 20 2 3 3 28
NNT 2 1 2 1
PNT 18 1 1 2
Chemotherapy
(-) 31 1 3 7 42
(+) 44 9 8 18 79
aSubjects followed by the 'General Rule for Clinical and Pathological Studies on Renal Pelvic and Ureteral Cancer'. Grade, tumour
grade; pT, depth of penetration; LY or V, lymphatic or venous invasion, M or N, distant organ orlymph node metastasis; growth, tumour
growth pattern; NNT, non-papillary non-invasive type; PNT, papillary non-invasive type; NIT, non-papillary invasive type; PIT, papillary
invasive type.
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Figure 2 The cumulative Kaplan-Meier survival curves of patients with
carcinoma of renal pelvis and ureter in each group. There were significant
differences between groups and IV (P < 0.001) and between groups IlIl and
IV (P< 0.001) (A). With respect to tumour grade, of the 73 patients with low-
grade TCC (grade 3 >, 3 < 2 or 1), there were significant differences between
each group (between groups I and IlIl, P< 0.01; land IV, P< 0.001; III and IV,
P < 0.001) (B). Of the 48 patients with high-grade TCCs (grade 3, 3 <), there
was also a significant difference between these two groups (P< 0.05) (C)
non-cancerous tissues, including the epithelium, stroma adjacent to
carcinoma and infiltrating inflammatory cells.
Mirror section analysis of cyclin E and p53
immunopositivity
In the present study, there was good correlation for the expression
between cyclin E and p53 protein in TCCs. Approximately 69%
of cyclin E-positive TCCs (69.4%; 25 out of 36) also displayed
positive reaction for p53, and there was a statistically significant
correlation for the expression between these two proteins
(P < 0.05). The mirror section technique revealed identical cancer
cell nuclei that were positive for both cyclin E and p53 in all five
tumours examined (Figure IA and IB).
In a previous study, we showed good correlation between p53
immunoreactivity and the presence ofp53 gene mutations concen-
trated on exons 4-9 in 26 cases (Furihata et al, 1995b). In the
present study, 5 of these 26 tumours, including four tumours with
both p53 gene point mutations and protein overexpression,
showed cyclin E immunoreactivity in the nucleus.
Statistical analysis
The patients were divided into the following four groups on the
basis of the pattem of tumour cell positivity for cyclin E and/or
p53; group I, 75 cases (62.0%), cyclin E-/p53-, group II, ten cases
(8.3%), cyclin E-/p53+; group III, 11 cases (9.0%), cyclin E+/p53-;
and group IV, 25 cases (20.7%), cyclin E+/p53+. Table 2 shows the
relationships between the rates of detection of overexpressed
cyclin E and/or p53 in primary tumours and clinical or patholog-
ical features. The relationship ofgroup IV with high nuclear grade
(P < 0.01) was statistically significant. In contrast, no significant
correlation was detected between cyclin E or p53 overexpression
and the other clinical and pathological parameters (sex, age,
tumour grade, depth ofpenetration, lymphatic or venous invasion,
distant organ or lymph node metastasis, tumour growth pattems
and treatment with chemotherapy). No significant correlation was
detected in the other three groups with any ofthe clinicopatholog-
ical factors analysed.
Association between cyclin E and/or p53
overexpression and prognosis
Figure 2A shows the Kaplan-Meier survival curves based on a
simultaneous comparison of the four groups of this cohort. The
post-operative 10-year survival rate ofgroup I (cyclin B /p53-) was
67.7%, while that of group IV (cyclin E+/p53+) was 15.2%. There
was a significant difference between these two groups (P < 0.001).
The post-operative 9-year survival rate ofgroup III (cyclin E+/p53-)
was 88.2%, while that of group IV was 15.2%. There was also a
significant difference between these groups (P < 0.001). In
contrast, there was no significant difference in the survival rate
between group I and group II (cyclin E-/p53+) or group III.
With respect to tumour grade, ofthe 73 patients with low-grade
TCC (grade 3 >, 3 < 2 or 1), the post-operative 5-year survival
rates of the groups I, III and IV were 74.8%, 97.6% and 13.8%
respectively. There were significant differences between each
group (between groups I and III, P < 0.01, I and IV, P < 0.001, III
and IV, P < 0.001) (Fig. 2B). Of the 48 patients with high-grade
TCC (grade 3, 3 <), the post-operative 9-year survival rate of
groups I and IV were 61.0% and 19.8%, respectively. There was
also a significant difference between these two groups (P < 0.05)
(Figure 2C).
To determine the most informative combination of independent
factors forprognosis, the variables identified as statistically signif-
icant in predicting survival (tumour grading, depth ofpenetration,
lymphatic or venous invasion, distant organ or lymph node
metastasis, tumour growth pattem and cyclin E and/or p53 over-
expression) were subjected to a multivariate analysis using Cox's
stepwise proportional hazard model. Each of these factors was
analysed to determine whether they had statistically significant
effects on the survival rate or not. A stepwise selection of these
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Table 3 Summary of the statistical analysis of prognostic factors using the
Cox proportional hazard model
Prognostic factors Hazard ratio Pvalue
(95% confidence limit)
Tumour grade 0.18 (0.04-0.82) <0.05
M or Na 9.20 (3.74-22.63) < 0.001
cyclin E and p53 8.20 (3.06-21.96) < 0.001
aDistant organ or lymph node metastasis.
factors was made, based on the relative magnitude of their contri-
bution to survival. As shown in Table 3, these analyses demon-
strated that the most important factor affecting survival was the
distant organ or lymph node metastasis (P < 0.001). Moreover,
simultaneous overexpression ofboth cyclin E and p53 was also an
important factor affecting survival (P < 0.001), as well as tumour
grade (P < 0.05).
DISCUSSION
We directly studied the relevance ofcyclin derangement to in vivo
conditions using immunohistochemistry assessing and analysing
the expression of both cyclin E and p53 proteins in tumour
samples from patients with TCCs. This immunohistochemical
study using antibodies to cyclin E and p53 was optimally designed
for precise measurement of the expression rates of these two
proteins and their expression patterns in individual tumour cells,
and this technique may be suitable for screening. In the present
study, 29.8% (36 out of 121) of the tumour samples showed posi-
tive immunoreaction with cyclin E antibody, which was predomi-
nantly revealed in the nuclei of cancer cells. We also detected the
overexpression of p53 protein in 35 TCCs, 25 of which showed
simultaneous positivity for cyclin E. In addition, the simultaneous
detection ofcyclin E and p53 protein overexpression was demon-
strated in identical cancer cell nuclei of TCCs. These findings
suggest that both cyclin E and p53 protein overexpression
frequently coexist in renal pelvic and ureteral TCCs.
The present study with urothelial TCC also revealed an inter-
esting and significant relationship between cyclin E andp53 protein
accumulation, demonstrating that the frequency of tumours with
simultaneous alterations in both cyclin E and p53 protein expres-
sions significantly increased along with the degree oftumour grade
(P < 0.01), revealing poorer prognosis (P < 0.001). Keyomarsi et al
(1994) demonstrated that cyclin E alterations become progressively
worse with increasing stage and grade of the breast carcinoma.
Recent reports have indicated thatp53 abnormalities are commonly
found in invasive and high-grade TCCs with poor prognosis
(Furihata et al, 1993). In the renal pelvic TCCs, however, Terrell et
al (1995) failed to show the significant association between p53
protein overexpression and established prognostic factors in 67
cases of TCCs. In the present study, we demonstrated additional
evidence that the combined evaluation ofcycin E and p53 overex-
pression may provide prognostic information that is more accurate
than the evaluation of p53 overexpression alone. Therefore, the
immunohistochemical detection ofboth cyclin E and p53 protein is
meaningful in the search for novel and potentially useful prognostic
markers in renal pelvic and ureteral TCC.
Evidence has been accumulated to support the presence of a
regulatory loop between cyclin E and pS3 protein involving various
Cdk inhibitors. In the molecular network of the normal cell cycle,
cyclin-Cdk complexes, which induce progression ofthe cell cycle,
are inactivatedby p2lwAF1/cw1, which is thought to be a downstream
target of p53 and serves as an effector of cell cycle arrest in
response to activation of p53 (Ei-Deiry et al, 1993; Harper et al,
1993). p21WAFl/CIPl inhibits different Cdks (Cdks 2,4/6), working in
conjunction with various cyclins (cyclin A, B, D, E) to alter the
activity of key proteins controlling entry into the different phases
(Gi, G1/S, S, G/M phase) of the cell cycle (Ei-Deiry et al, 1993;
Harper et al, 1993; Cross et al, 1995). In mammalian cells, the
cyclin E-Cdk2 complex plays an important role in the G,/S phases
(Cordon-Cardo, 1995). In the present study of 26 tumours, which
had already been examined for p53 mutations by comparing the
immunohistochemical reactivity (Furihata et al, 1995b), cyclin E
immunoreactivity was detected in five cyclin E-positive tumours,
including four tumours with bothp53 gene mutations and accumu-
lation ofits products. Recently, Akama et al (1996) studied the rela-
tionship between p53 mutations and the expression ofp21WAFl/cwPl
or cyclins in human gastric cancer cell lines and showed the corre-
lation between p53 gene mutations and very low or undetectable
levels of p2lWAFI/cPl mRNA expression. In addition, an inverse
correlation was simultaneously shown between the level of
p2lWAF1/cPl and cyclin E mRNA in the same cell lines examined
(Akama et al, 1996). Elbendary et al (1996) also showed that muta-
tion of the p53 gene was associated with decreased p2lwAF1/cwIP
expression in human ovarian cancers. A recent immunohistochem-
ical study in human breast carcinoma showed that most tumours
with p53 gene mutations revealed low to absent p21WAFI/CIPI
immunoreactivity (Barbareschi et al, 1996). Although the effects of
unscheduled overexpression of cyclin E intimately related to p53
alteration in the development ofTCC have not yet been explored, it
is interesting to speculate that alteration of the p53 gene, leading
to accumulation of its product, cannot induce activation of Cdk
inhibitors, such as p21WAFi1cIP1, and thus additional cancer-
promoting genetic alterations through G1/S phases ofthe cell cycle,
including those related to aberrant cyclin E gene transactivation
leading to post-transcriptional overexpression of its product, may
follow. On the other hand, recent studies have revealed ap53-inde-
pendent pathway ofp2lwAF1/cIP1 gene activation in primary embryo
fibroblasts (Michiele et al, 1994), human promyelocytic HL-60
leukaemia cells (Jiang et al, 1994) and human breast cancer cells
(Sheikh etal, 1994). Although the molecular basis forthe activation
ofCdk inhibitors, including the p2IwAF1/cIPl gene, is still indefinite,
ourfindings that 11 cases were immunohistochemically positive for
cyclin E but negative for p53 may also suggest in part that p53 is
not the sole regulator ofthe upstream pathway in the cyclin E gene
expression which is inhibited by activating the p2lWAFI/cIPl gene.
With respect to cyclin E abnormality in tumorigenesis, little direct
experimental evidence exists supporting the correlation between
cyclin E gene alterations, such as gene amplification ortransforma-
tion, and overexpression of its product (Keyomarsi and Pardee,
1993; Keyomarsi et al, 1995; Courjal et al, 1996). In order to deter-
mine whether both p53 and cyclin E alterations enhance genetic
changes during the progression of the renal pelvic and ureteral
TCC, the relationship betweenp53 gene abnormalities and subse-
quent transactivation or genetic changes ofeach cyclin gene, espe-
cially of cyclin E, which promotes an advance in the cell cycle of
tumour cells, should be further examined.
In conclusion, this is the first report of frequent cyclin E protein
overexpression in association with p53 alteration in a large series of
primary human renal pelvic and ureteral TCCs. In addition, the
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present study also demonstrates that simultaneous overexpression of
both cyclin E and p53 protein may be important prognostic indica-
tors and may be potentially useful for assessing tumour aggressive-
ness. Furthercomprehensive studiesusing excisedhumancarcinoma
tissue samples in greater numbers, including measurement of DNA
and/or RNA levels, will be required to confirm these results.
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